Resources
159 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 11/19/2019 (updated 3/25/2024)
Although typically delivered via intramuscular or intravenous injection, naloxone may be delivered via intranasal spray device.
Posted 11/24/2021 (updated 3/26/2024)
This webinar will provide participants with an understanding of the role of the medical examiners and coroners in the surveillance of drug overdose deaths, as well as the current efforts to strengthen the death investigation system. The webinar will also cover an overview of the overdose fatality review process and tools available for implementation.
Posted 12/22/2021 (updated 3/26/2024)
This Rural Health Care Chartbook is part of a family of documents and tools that support the National Healthcare Quality and Disparities Report (NHQDR). The NHQDR includes annual reports to Congress mandated in the Healthcare Research and Quality Act of 1999 (P.L. 106- 129). These reports provide a comprehensive overview of the quality of healthcare received by the general U.S. population and disparities in care experienced by different racial, ethnic, and socioeconomic groups. The reports assess the performance of our health system and identify areas of strength and weakness in the healthcare system along four main axes: access to healthcare, quality of healthcare, disparities in healthcare, and Agency for Healthcare Research and Quality (AHRQ) priority areas. The reports are based on more than 250 measures of quality and disparities covering a broad array of healthcare services and settings. Data are generally available through 2017-2018. The reports are produced with the help of an Interagency Work Group led by AHRQ and submitted on behalf of the Secretary of Health and Human Services (HHS).
Posted 1/5/2022 (updated 3/26/2024)
This brief reviews the history, harms, pathways and trends that treat children as if they were adults
Posted 7/28/2023 (updated 3/26/2024)
The toolkit Stimulant Safety: Getting Amped Up to Reduce Harms When Using Stimulants was developed through the CDC-funded National Harm Reduction Technical Assistance Center in collaboration with the NASTAD Drug User Health team and consultants. This resource provides education on the reasons people take stimulants, how to minimize harm, reduce stigma around stimulants, support peoples' positive experiences, the intersection of stimulant use and sexual safety, and much more.
Posted 7/31/2023 (updated 3/26/2024)
At the end of July 2023, the U.S. Food and Drug Administration approved a second over-the-counter naloxone nasal spray product, RiVive. The agency who received the approval to manufacture the product, Harm Reduction Therapeutics, does not yet have a timeline of availability and decision on pricing.
Posted 8/11/2023 (updated 3/26/2024)
The Center of Excellence for Integrated Health Solutions (funded by Substance Abuse and Mental Health Services Administration and operated by the National Council for Mental Wellbeing) and the School-Based Health Alliance now has a guide to help mental health organizations have successful partnerships with schools as a way to help the mental health and substance use care for K-12 students. The guide provides information to consider, as well as resource recommendations.
Posted 9/4/2023 (updated 3/26/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has created a toolkit for National Recovery Month 2023 to support people in recovery from mental and substance use disorders. The toolkit includes social media content material, resources for recovery, and recovery promotional materials.
Posted 9/5/2023 (updated 3/26/2024)
Visit the Substance Abuse and Mental Health Services Administration (SAMHSA) to learn more about National Recovery Month, held every September. National Recovery Month is dedicated to promoting and supporting new evidence-based treatment and recovery practices. Find events, read President Biden's proclamation on National Recovery month, and discover many resources which can be utilized in your organization and community.
Posted 3/3/2022 (updated 3/26/2024)
The US overdose crisis is driven by fentanyl, heroin, and prescription opioids. One evidence-based policy response has been to broaden naloxone distribution, but how much naloxone a community would need to reduce the incidence of fatal overdose is unclear. We aimed to estimate state-level US naloxone need in 2017 across three main naloxone access points (community-based programs, provider prescription, and pharmacy-initiated distribution) and by dominant opioid epidemic type (fentanyl, heroin, and prescription opioid).